Our Vision:

With a record-breaking 8,500 abstracts submitted, including more than 1,000 focused on multiple myeloma, the insights will surely be enlightening. In this week’s blog, IMF Chief Medical Officer Dr. Joseph R. Mikhael (“Dr. Joe”) has handpicked 10 must-read oral and poster abstracts as a sampling of the incredible research work being done in the field of myeloma. From cutting-edge CAR T-cell therapies to game-changing quadruplet regimens, this curated list will give you a sneak peek of the transformative work happening in myeloma research. READ THE BLOG. 

Many Medicare Part D plans may be dropping Revlimid from their formularies in 2025, and Open Enrollment ends December 7. If you rely on Revlimid, read this news article to learn how to check your 2025 Medicare coverage now, the steps to take if your plan won’t cover Revlimid next year, and options available even after Open Enrollment closes. This situation is evolving, but there are actions you can take today to protect your access to Revlimid. Read the full article from Triage Cancer: READ NOW.

The International Myeloma Foundation (IMF) is proud to announce that IMF Medical Student Scholar for Health Equity Semegne Hiruy (Wake Forest University School of Medicine—Winston-Salem, NC) is among the recipients of the 2024 ASH Achievement Awards. Her groundbreaking research explores treatment outcomes in Black patients with multiple myeloma, shining a spotlight on the need for tailored therapeutic approaches based on genetic risk factors. Under the mentorship of Dr. Manisha Bhutani, Semegne’s work underscores the vital role of equity-focused research in addressing health disparities. Join us in congratulating Semegne and Dr. Bhutani, as well as our IMF Medical Student Scholars who will also be presenting their posters at ASH 2024. READ THE NEWS ARTICLE.

At the upcoming International Myeloma Working Group (IMWG) Conference Series: “Making Sense of Treatment,” leading experts will discuss key advances in multiple myeloma research from the 2024 American Society of Hematology (ASH) Conference. Moderated by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACPP (TGen at the City of Hope – Phoenix), the panel includes IMF Nurse Leadership Board Member Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (Cleveland Clinic, Taussig Cancer Center – Cleveland); Nikhil Munshi, MD (Dana-Farber Cancer Institute – Boston); and IMF Chairperson of the Board S. Vincent Rajkumar, MD (Mayo Clinic – Rochester, MN). Topics will cover monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), current challenges, frontline therapies, immune therapies such as CAR T-cell and bispecific antibodies, and novel drugs. Dr. Mikhael will share highlights from the ASH abstracts and the IMF IMWG Breakfast. Don’t miss this live event on December 18, 2024! SAVE MY SEAT. 

Tune in as the IMF brings myeloma support group leaders and patients to the hybrid 66th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 10,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH24 and #IMFASH24), Facebook, blogs, and videos. VISIT THE WEBSITE NOW.

The International Myeloma Foundation's Boca Raton 5K is a community event focused on raising awareness and funds for multiple myeloma research, support, and education. Participants can join in-person or virtually to support this cause. The event encourages community involvement through running, walking, or fundraising efforts. LEARN MORE.